BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Girges C, Vijiaratnam N, Athauda D, Auld G, Gandhi S, Foltynie T. The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. Drugs Aging 2021;38:355-73. [PMID: 33738783 DOI: 10.1007/s40266-021-00853-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Nowell J, Blunt E, Edison P. Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease. Mol Psychiatry 2023;28:217-29. [PMID: 36258018 DOI: 10.1038/s41380-022-01792-4] [Reference Citation Analysis]
2 Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 2022;239:108277. [DOI: 10.1016/j.pharmthera.2022.108277] [Reference Citation Analysis]
3 Vijiaratnam N, Foltynie T. Disease modifying therapies III: Novel targets. Neuropharmacology 2021;201:108839. [PMID: 34656651 DOI: 10.1016/j.neuropharm.2021.108839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 González LF, Bevilacqua LE, Naves R. Nanotechnology-Based Drug Delivery Strategies to Repair the Mitochondrial Function in Neuroinflammatory and Neurodegenerative Diseases. Pharmaceutics 2021;13:2055. [PMID: 34959337 DOI: 10.3390/pharmaceutics13122055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]